small molecule

ORLYNVAH

PROBENECID; SULOPENEM ETZADROXIL

Loss of exclusivityDecember 2039latest FDA-listed patent expiry

CompanyIterum Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	ORLYNVAH
Active ingredient	PROBENECID; SULOPENEM ETZADROXIL
Strength	500MG;500MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12544337	December 2039	product
11478428	December 2039	product
12109197	April 2039	use U-4026
11554112	April 2039	use U-4026
7795243	June 2029	substance, product

Regulatory exclusivity

Code	Expires
GAIN	October 2034
NCE	October 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.